The relationship between MOG-Ab titers and clinical disease activity, however, remains an area of active investigation, with a recent report suggesting that a high MOG-Ab titer (≥ 1:1280) predicted a recurrent non-MS course with a sensitivity of 46% and a specificity of 86% [17•]. Here, MOG is linked to myeloid sarcoma.